Mineralys Therapeutics (NASDAQ:MLYS) Insider Sells $11,505.03 in Stock

Mineralys Therapeutics, Inc. (NASDAQ:MLYS) insider David Malcom Rodman sold 417 shares of the firm’s stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $27.59, for a total value of $11,505.03. Following the sale, the insider owned 44,089 shares in the company, valued at $1,216,415.51. The trade was a 0.94% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

David Malcom Rodman also recently made the following trade(s):

• On Thursday, February 12th, David Malcom Rodman sold 6,349 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $28.99, for a total value of $184,057.51.
• On Friday, February 13th, David Malcom Rodman sold 14,055 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $27.44, for a total value of $385,669.20.
• On Monday, February 9th, David Malcom Rodman sold 2,171 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $30.21, for a total value of $65,585.91.
• On Tuesday, January 20th, David Malcom Rodman sold 416 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $32.10, for a total transaction of $13,353.60.
• On Wednesday, January 14th, David Malcom Rodman sold 11,367 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $32.61, for a total transaction of $370,677.87.
• On Tuesday, January 13th, David Malcom Rodman sold 7,709 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $32.75, for a total value of $252,469.75.
• On Monday, January 12th, David Malcom Rodman sold 6,348 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $32.32, for a total value of $205,167.36.
• On Friday, January 9th, David Malcom Rodman sold 2,170 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $33.27, for a total value of $72,195.90.
• On Friday, January 2nd, David Malcom Rodman sold 70,037 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $35.87, for a total value of $2,512,227.19.
• On Monday, January 5th, David Malcom Rodman sold 192,715 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $35.02, for a total transaction of $6,748,879.30.

Mineralys Therapeutics Stock Performance

Shares of MLYS opened at $27.82 on Friday. The stock has a market cap of $2.20 billion, a PE ratio of -9.51 and a beta of 0.51. The firm’s 50-day simple moving average is $33.18 and its two-hundred day simple moving average is $33.79. Mineralys Therapeutics, Inc. has a fifty-two week low of $8.24 and a fifty-two week high of $47.65.

Institutional Investors Weigh In On Mineralys Therapeutics

Large investors have recently made changes to their positions in the company. Simplify Asset Management Inc. bought a new stake in Mineralys Therapeutics in the third quarter worth $8,294,000. Geode Capital Management LLC raised its holdings in Mineralys Therapeutics by 19.0% during the 2nd quarter. Geode Capital Management LLC now owns 954,560 shares of the company’s stock valued at $12,917,000 after buying an additional 152,560 shares during the period. 22NW LP raised its holdings in shares of Mineralys Therapeutics by 21.4% in the second quarter. 22NW LP now owns 560,042 shares of the company’s stock worth $7,577,000 after buying an additional 98,698 shares during the period. Voya Investment Management LLC boosted its holdings in Mineralys Therapeutics by 174.4% during the 3rd quarter. Voya Investment Management LLC now owns 138,526 shares of the company’s stock valued at $5,253,000 after acquiring an additional 88,050 shares during the period. Finally, Pale Fire Capital SE increased its stake in Mineralys Therapeutics by 11.8% in the second quarter. Pale Fire Capital SE now owns 446,626 shares of the company’s stock worth $6,043,000 after purchasing an additional 47,128 shares during the period. 84.46% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on the company. Stifel Nicolaus upped their price objective on Mineralys Therapeutics from $45.00 to $52.00 and gave the stock a “buy” rating in a research note on Friday, December 19th. Weiss Ratings restated a “sell (d-)” rating on shares of Mineralys Therapeutics in a research report on Thursday, January 22nd. Wells Fargo & Company upped their price target on shares of Mineralys Therapeutics from $50.00 to $55.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 11th. Finally, HC Wainwright upped their price objective on Mineralys Therapeutics from $52.00 to $56.00 and gave the stock a “buy” rating in a research note on Wednesday, November 12th. Six research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $47.43.

About Mineralys Therapeutics

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc and changed its name to Mineralys Therapeutics, Inc in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.